128 related articles for article (PubMed ID: 3187945)
1. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship.
Thijssen HH; Hamulyák K; Willigers H
Thromb Haemost; 1988 Aug; 60(1):35-8. PubMed ID: 3187945
[TBL] [Abstract][Full Text] [Related]
2. The interaction of the prostaglandin E derivative rioprostil with oral anticoagulant agents.
Thijssen HH; Hamulyàk K
Clin Pharmacol Ther; 1989 Jul; 46(1):110-6. PubMed ID: 2501056
[TBL] [Abstract][Full Text] [Related]
3. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
[TBL] [Abstract][Full Text] [Related]
4. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
van Leeuwen Y; Rosendaal FR; van der Meer FJ
Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
[TBL] [Abstract][Full Text] [Related]
5. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
6. Detection of drug interactions with single dose acenocoumarol: new screening method?
Kroon C; de Boer A; Hoogkamer JF; Schoemaker HC; van der Meer EJ; Edelbroek PM; Cohen AF
Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):355-60. PubMed ID: 2272718
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.
Haustein KO
Semin Thromb Hemost; 1999; 25(1):5-11. PubMed ID: 10327214
[TBL] [Abstract][Full Text] [Related]
8. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
[TBL] [Abstract][Full Text] [Related]
9. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
10. The effect of daily administration of naproxen on the prothrombin complex activity in patients under long-term therapy with phenprocoumon.
Petersen PB; Husted S; Mortensen A; Andreasen F
Scand J Rheumatol; 1979; 8(1):54-6. PubMed ID: 311940
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial.
Gadisseur AP; Breukink-Engbers WG; van der Meer FJ; van den Besselaar AM; Sturk A; Rosendaal FR
Arch Intern Med; 2003 Nov; 163(21):2639-46. PubMed ID: 14638565
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
Eur J Clin Pharmacol; 1999 Jan; 54(11):857-64. PubMed ID: 10027661
[TBL] [Abstract][Full Text] [Related]
13. [The treatment basis for anticoagulants in horses].
Sinn D; Wintzer HJ
Tierarztl Prax; 1990 Oct; 18(5):507-11. PubMed ID: 2264055
[TBL] [Abstract][Full Text] [Related]
14. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
Rombouts EK; Rosendaal FR; van der Meer FJ
Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
[TBL] [Abstract][Full Text] [Related]
15. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
[TBL] [Abstract][Full Text] [Related]
16. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
[TBL] [Abstract][Full Text] [Related]
17. A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit.
Breckenridge AM; Cholerton S; Hart JA; Park BK; Scott AK
Br J Pharmacol; 1985 Jan; 84(1):81-91. PubMed ID: 3978316
[TBL] [Abstract][Full Text] [Related]
18. Measurement of fibrinopeptide A in patients treated with phenprocoumon.
Harenberg J; Haas R; Zimmermann R
Thromb Haemost; 1981 Jun; 45(3):282-4. PubMed ID: 7281107
[TBL] [Abstract][Full Text] [Related]
19. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study.
Lorenz R; Kienast J; Otto U; Kiehl M; Schreiter D; Haertel S; Barthels M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):565-70. PubMed ID: 17762533
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
Kohl C; Steinkellner M
Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
